國家衛生研究院 NHRI:Item 3990099045/15752

NHRI > National Institute of Infectious Diseases and Vaccinology > Others > Periodical Articles > Item 3990099045/15752

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15752

Title:	Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV
Authors:	Liu, WD;Lin, MS;Sun, HY;Shih, MC;Chuang, YC;Huang, YS;Lin, KY;Li, GC;Wu, PY;Chen, LY;Liu, WC;Su, YC;He, PC;Chen, YT;Lin, CY;Cheng, YC;Yao, Y;Yeh, YC;Liu, CC;Pan, MY;Luo, YZ;Chang, HY;Wang, JT;Sheng, WH;Hsieh, SM;Chang, SY;Hung, CC
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	Background: Real-world vaccine effectiveness following the third dose of vaccination against SARS-CoV-2 remains less investigated among people with HIV (PWH). Methods: PWH receiving the third dose of BNT162b2 and mRNA-1273 (either 50- or 100-μg) were enrolled. Participants were followed for 180 days until the fourth dose of COVID-19 vaccination, SARS-CoV-2 infection, seroconversion of anti-nucleocapsid IgG, death, or loss to follow-up. Anti-spike IgG was determined every 1–3 months. Results: Of 1427 participants undergoing the third-dose COVID-19 vaccination, 632 (44.3%) received 100-μg mRNA-1273, 467 (32.8%) 50-μg mRNA-1273, and 328 (23.0%) BNT162b2 vaccine and the respective rate of SARS-CoV-2 infection or seroconversion of anti-nucleocapsid IgG was 246.1, 280.8 and 245.2 per 1000 person-months of follow-up (log-rank test, p = 0.28). Factors associated with achieving anti-S IgG titers >1047 BAU/mL included CD4 count <200 cells/mm3 (adjusted odds ratio [aOR], 0.11; 95% CI, 0.04–0.31), plasma HIV RNA >200 copies/mL (aOR, 0.27; 95% CI, 0.09–0.80), having achieved anti-spike IgG >141 BAU/mL within 3 months after primary vaccination (aOR, 3.69; 95% CI, 2.68–5.07), receiving BNT162b2 vaccine as the third dose (aOR, 0.20; 95% CI, 0.10–0.41; reference, 100-μg mRNA-1273), and having previously received two doses of mRNA vaccine in primary vaccination (aOR, 2.46; 95% CI, 1,75-3.45; reference, no exposure to mRNA vaccine). Conclusions: PWH receiving different types of the third dose of COVID-19 vaccine showed similar vaccine effectiveness against SARS-CoV-2 infection. An additional dose with 100-μg mRNA-1273 could generate a higher antibody response than with 50-μg mRNA-1273 and BNT162b2 vaccine.
Date:	2024-08
Relation:	Journal of Microbiology, Immunology and Infection. 2024 Aug;57(4):554-563.
Link to:	http://dx.doi.org/10.1016/j.jmii.2024.02.004
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1684-1182&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001296649300001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85186348182
Appears in Collections:	[Others] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85186348182.pdf		816Kb	Adobe PDF	46	View/Open

Loading...